Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4504 | hormones Wiki | 0.71 |
| drug4501 | high-titer anti-Sars-CoV-2 plasma Wiki | 0.71 |
| drug4576 | mesenchymal stem cells Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D017563 | Lung Diseases, Interstitial NIH | 0.19 |
| D011014 | Pneumonia NIH | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006515 | Interstitial pneumonitis HPO | 0.19 |
| HP:0002090 | Pneumonia HPO | 0.07 |
Navigate: Correlations HPO
There are 2 clinical trials
Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.
Description: reduction in oxygen and ventilation support
Measure: reduction in oxygen and ventilation support Time: through study completion, an average of 4 weeksThe outbreak of coronavirus disease 2019 (COVID-19) at the end of 2019 has seen numerous patients experiencing severe acute lung injury (ALI), which developed into severe respiratory distress syndrome (ARDS). The mortality was as high as 20% -40%. Due to the lack of effective antiviral treatments, supporting treatment is the predominant therapy for COVID-19 pneumonia. Its cure is essentially dependent on the patient's immunity. While the immune system eliminates the virus, numerous inflammatory cytokines are produced and a cytokine storm occurs in severe cases. Mesenchymal stem cells (MSCs) play an important role in injury repair and immune regulation, showing advantageous prospects in the treatment of COVID-19 pneumonia. MSCs prevent cytokine storms by retarding the TNF-α pathway, alleviate sepsis by modulating macrophages, neutrophils, NK cells, DC cells, T lymphocytes and B lymphocytes. After infused, MSCs aggregate in the lungs, improve the lung microenvironment, protect alveolar epithelia, and improve pulmonary fibrosis and pulmonary function.
Description: Improvement of pulmonary function
Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 12 monthsDescription: Cytokines level
Measure: Detection of TNF-α levels, IL-10 levels Time: 1,3,6,12monthsDescription: Immunological status
Measure: Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells). Time: 1,3,6,12monthsDescription: Improvement of pulmonary function
Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 1,3,6monthsDescription: Infection biomarkers
Measure: Changes of c-reactive protein and calcitonin Time: 1,3,6,12monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports